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Background: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered
to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this
phase 2 dose-finding study was to determine the once-monthly peginesatide dosing strategy that would maintain
hemoglobin within ±1.0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was
evaluated concurrently.
Methods: Chronic hemodialysis patients on stable regimens of epoetin alfa were sequentially assigned to cohorts
that differed on (1) how the peginesatide starting dose was determined (using a single epoetin alfa–to-
peginesatide dose conversion ratio or a tiered, weight-based or absolute-dose conversion table) and on (2) whether
or not a 1-week erythropoiesis-stimulating agent-free interval was used. Peginesatide doses were titrated to
maintain hemoglobin levels within ±1.0 g/dL from baseline.
Results: A total of 164 patients were enrolled and received intravenous peginesatide every 4 weeks for up to 6
doses; the duration of the study including follow-up was ≤29 weeks. Overall, the proportion of patients with
hemoglobin levels within ±1.0 g/dL of baseline increased over the course of the study from 39% (Weeks 2–13) to
54% (Weeks 18–25). Cohorts that used tiered dose conversion tables trended towards having more stable
peginesatide doses than did those cohorts that used a single dose conversion ratio. Moreover, cohorts that used an
erythropoiesis-stimulating agent-free interval did not have the substantial initial increase in hemoglobin levels that
was seen in those cohorts that did not use such an interval. In this study, the safety profile of peginesatide was
consistent with those of marketed erythropoiesis-stimulating agents.
Conclusions: The results of this study were used to guide the dosing regimens used subsequently in phase 3
studies. Once-monthly peginesatide is feasible in hemodialysis patients.
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Anemia associated with chronic kidney disease (CKD)
contributes to increased morbidity and a decreased qual-
ity of life [1,2]. Standard therapies for CKD-associated
anemia are erythropoiesis-stimulating agents (ESAs),
which have been shown to increase and maintain
hemoglobin (Hb) levels leading to a decreased need for
red blood cell transfusions [3]. These agents have also
been associated with an increased risk of death and car-
diovascular events in clinical trials targeting normalized
hemoglobin levels [4-7].
Peginesatide, a synthetic ESA that was designed and
engineered to stimulate specifically the erythropoietin
receptor dimer that governs erythropoiesis, is composed
of a dimeric peptide that is linked to a polyethylene gly-
col moiety [8]. The amino acid sequence of peginesatide
is unrelated to that of erythropoietin; therefore, pegine-
satide is unlikely to induce a cross-reactive immune re-
sponse against either endogenous or recombinant
erythropoietin. Following intravenous administration,
the half life of peginesatide is approximately 48 hours in
dialysis patients and 25 hours in healthy subjects [7],
suggesting that peginesatide clearance varies inversely
with kidney function. Peginesatide has been shown to in-
crease Hb in patients with anti-erythropoietin antibody-
mediated pure red cell aplasia [9]. In healthy volunteers,
peginesatide had a safety profile similar to that of pla-
cebo and was associated with a significant increase in
Hb that sustained for over 1 month [10].
Results of a phase 2, dose-finding study of once-
monthly (Q4W) peginesatide for the maintenance of Hb
levels in chronic hemodialysis patients who were
switched from epoetin alfa are reported herein. The pri-
mary objective of this study was to determine the pegi-
nesatide dosing strategy that would maintain Hb within
±1.0 g/dL of baseline values after conversion from epoe-
tin alfa; the safety of peginesatide was also assessed.
Methods
Patients
Adult CKD patients were eligible if they had been clinically
stable on hemodialysis for ≥6 months, had received epoetin
alfa for ≥8 weeks, had 3 stable Hb values within 10.0 to
12.5 g/dL and evidence of adequate iron stores. The main
exclusion criteria were intolerance to ESAs or parenteral
iron supplementation, a history of antibodies to ESAs or
pure red cell aplasia (see Additional file 1: Table S1 for
complete inclusion and exclusion criteria).
Study design
In this multicenter (14 centers in the United States),
phase 2, open-label, sequential, dose-finding study,
patients were administered intravenous Q4W peginesa-
tide during dialysis, for a total of 6 doses. The durationof the study was ≤29 weeks. Participating sites received
approval from their governing institutional review
board (Henry Ford Health System IRB; Committee on
Scientific Activities/IRB, Beth Israel Medical Center;
Coast IRB, LLC; Human Subjects Research Committee,
Minneapolis Medical Research Foundation). All patients
provided written informed consent, and the study was
performed in accordance with the Helsinki Declaration of
1975 (and as revised in 1983) and the ICH guidelines for
Good Clinical Practice (ClinicalTrials.gov registration:
NCT00228449).
The study design allowed for multiple cohorts of 15
patients each. Cohorts differed with respect to the strategy
used to determine the starting dose of peginesatide: (1)
either a single epoetin alfa–to-peginesatide dose conver-
sion ratio or a tiered, weight-based or fixed-dose conver-
sion table and (2) whether or not an ESA-free interval
(epoetin alfa dosing stopped 1 week before the first dose)
was used. In the first cohort, a single epoetin alfa–
to-peginesatide dose conversion ratio of approximately
3000 U/wk of epoetin alfa to 1 mg/mo of peginesatide
without an ESA-free interval was used. Subsequent
cohorts were added on the basis of ongoing Hb and safety
results, with 15 patients assigned sequentially to each
cohort. Hemoglobin data from previous cohort(s) guided
peginesatide starting doses and whether or not ESA-free
intervals were used. The study allowed for repeating
cohorts with identical dosing strategies.
After the first dose of peginesatide, each patient’s sub-
sequent doses were adjusted using predetermined
guidelines (Additional file 2: Table S2) to maintain Hb
within ±1.0 g/dL of baseline; Hb levels, and adverse
events (AEs) were assessed weekly. Investigators main-
tained iron levels according to the KDOQI treatment
guidelines. Vital signs and clinical laboratory parameters
were assessed periodically. 12-lead ECGs were evaluated
during screening and 30 minutes after the first pegine-
satide dose. Blood samples to assess for antibodies to
peginesatide were collected at each peginesatide dosing
visit and at study termination. Patients were followed
for ≥42 days after their last dose (unless they were en-
rolled in a long-term peginesatide extension study) or
until the stabilization of AEs, whichever occurred later.
Study drug
Peginesatide (formerly known as Hematide™; Affymax, Inc.,
Palo Alto, CA) was supplied as a preservative-free, aseptic-
ally manufactured, sterile parenteral solution provided in a
2-mL, single-use, clear glass vial. Each vial contained 1 mL
of solution at a concentration of 10 mg/mL peginesatide in
an acetate-buffered saline solution at pH 5.5 (±0.5) or in an
isotonic phosphate-buffered solution at pH 6.0 (±0.5). The
formulation was changed from an acetate-buffered solution
to a phosphate-buffered solution to improve stability.
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Dosing requirements were calculated using the median
peginesatide dose for each cohort, stratified by the num-
ber of the injections. Efficacy variables for each cohort
were mean Hb concentration and mean Hb change from
baseline (the mean of the 3 most recent mid- or end-
of-week predialysis Hb values collected in the 3 weeks
before the start of the study). The number and percent-
age of patients who maintained Hb values within 9.5 to
13.0 g/dL and within 11.0 to 13.0 g/dL for each cohort
were also assessed. The upper bound of 13.0 g/dL was
used for these targets to permit Hb level variations
within ±1.0 g/dL of baseline values (entry Hb levels
could range from 10.0 to 12.5 g/dL); the upper bound of
12.5 g/dL was not used to avoid potentially excessive
dose titration. Hemoglobin data collected subsequent to
a phlebotomy, or 4 weeks subsequent to a transfusion or
bleeding event, were excluded. Safety was assessed via
the collection of AEs and SAEs assessed by the investi-
gators as related or unrelated to the study drug. All AEs
were graded by severity using the WHO toxicity criteria
(ie, grades 1, 2, 3, and 4, considered mild, moderate,
severe, and life threatening, respectively). Other safety
end points were: reasons for study withdrawal, number
of transfusions and phlebotomies, iron parameters,
changes in clinical laboratory results, 12-lead ECGs and
vital signs, and evaluations of antibodies to peginesatide
(both neutralizing and non-neutralizing).
Statistical analysis
Cohorts with identical starting doses and dosing strat-
egies were summarized together. Number and percent-
































Abbreviation: AE, adverse event.
aOne patient was withdrawn from the study because of an
AE before receiving the study drug.
Figure 1 Patient disposition.measures, and the number of observations, mean, me-
dian, and standard deviation were used for continuous
measures. Summary statistics were presented for each
dose group. Patients who received ≥1 dose of study drug
were included in all analyses. Because of the small num-
bers of patients in each of the cohorts and their sequen-
tial nature, no formal comparisons, including baseline
characteristics, between cohorts were performed.
Results
Patient characteristics and disposition
This study was conducted from July 2005 to May 2007.
A total of 165 patients were enrolled (Figure 1) and
assigned to 1 of 11 cohorts of 15 patients each; 3 differ-
ent pairs of cohorts had identical starting doses and dos-
ing strategies and were combined into single cohorts of
30 patients each (cohorts D, G, and H; Table 1), leaving
8 cohorts for analysis (Table 1). Single epoetin alfa–
to-peginesatide dose conversion ratios were used in
Cohorts A to E, whereas tiered (weight-based or abso-
lute-dose) dose conversion tables were used in Cohorts
F to H. Conversion from epoetin alfa to peginesatide
without an ESA-free interval was investigated in Cohorts
A, B, C, G, and H, whereas conversion with an ESA-free
interval was investigated in Cohorts D, E, and F.
All but 1 of the 165 enrolled patients received ≥1 dose
of peginesatide and were included in the analyses. One
patient (enrolled in Cohort C), who experienced a fatal
cardiac arrest before receiving the study drug, was not
included.
Thirty-eight patients were withdrawn from the study: 12
patients because of AEs (detailed in the Safety section), 4






















Table 1 Dosing cohorts









A 15 Dose conversion ratio NA NA 3030:1 No
B 15 Dose conversion ratio NA NA 2439:1 No
C 14 Dose conversion ratio NA NA 2000:1 No
D 30 Dose conversion ratio NA NA 2000:1 Yes
E 15 Dose conversion ratio NA NA 1515:1 Yes
F 15 Tiered weight-based <100 U/kg 0.050 mg/kg <2000:1 Yes
100 to 150 U/kg 0.075 mg/kg 1333 to 2000:1
> 150 to 200 U/kg 0.100 mg/kg 1500 to 2000:1
>200 U/kg 0.150 mg/kg >1333:1
G 30 Tiered weight-based <100 U/kg 0.050 mg/kg <2000:1 No
100 to 150 U/kg 0.075 mg/kg 1333 to 2000:1
>150 to 200 U/kg 0.100 mg/kg 1500 to 2000:1
>200 U/kg 0.150 mg/kg >1333:1
H 30 Tiered fixed-dose <8000 U 4.0 mg <2000:1 No
8000 to 16000 U 6.0 mg 1333 to 2666:1
>24000 U 12.0 mg 1333 to 2000:1
16.0 mg >1500:1
Abbreviation: ESA, erythropoiesis-stimulating agent.
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tin alfa, n = 4; darbepoetin alfa, n = 2; cocaine, n = 1) and
patient moved geographically or transferred to another
non-participating center (n = 3). Six patients were with-
drawn because of a lack of effectiveness; 5 were in cohorts
that had the lowest relative starting doses of peginesatide
(Cohorts A and B) and 1 was in a cohort that had a higher
relative starting dose (Cohort D). These 6 patients
received 3 or 4 doses before discontinuation, and their
mean change from baseline Hb level to the time of discon-
tinuation was -1.1 g/dL.
Baseline and demographic characteristics are detailed
in Table 2. The majority of patients were men (57%) and
black (56%). The median dose of epoetin alfa at baseline
was 137 U/kg/wk and the mean (SD) Hb at baseline was
11.5 (0.6) g/dL. During the 8 weeks before study drug
treatment, 141 patients (86%) received intravenous epoe-
tin alfa, 22 patients (13%) received subcutaneous epoetin
alfa, and 1 patient (<1%) received both intravenous and
subcutaneous epoetin alfa.
Peginesatide dosing
Overall, the median peginesatide dose increased from
Dose 1 (0.073 mg/kg) to Dose 6 (0.085 mg/kg). The me-
dian dose of peginesatide tended to increase more in those
cohorts in which a single epoetin alfa–to-peginesatide
dose conversion ratio was used (Figure 2A), except forCohort E, in which the highest relative starting dose (mg/
kg) of peginesatide was used. Although median peginesa-
tide doses also tended to increase in those cohorts in
which tiered conversion tables were used (Figure 2B), this
effect was not as pronounced as it was in those cohorts in
which single dose conversion ratios were used. Of note,
peginesatide doses were adjusted after the first dose to
maintain Hb within ±1 g/dL of the baseline concentration
and comparisons of dose requirements between groups is
complicated by differences in the initial dosing regimen.
Efficacy
Overall, the proportion of patients with Hb levels within
±1.0 g/dL of baseline increased over the course of the
study from 39% (Weeks 2–13) to 54% (Weeks 18–25). Fol-
lowing the initial dose, increases in mean Hb levels during
the first several weeks were evident in those cohorts that
did not use an ESA-free interval (Cohorts A, B, C, G, and
H; Figure 3A). This initial increase generally was not evi-
dent in those cohorts using an ESA-free interval (Cohorts
D, E, and F; Figure 3B); the only exception to this was Co-
hort E. This may reflect the higher relative starting dose
that was used in Cohort E, compared with that of Cohort
D. In addition, a single epoetin alfa–to-peginesatide dose
conversion ratio was used in Cohort E, whereas a tiered
weight-based dose conversion table was used in Cohort F.



















Age, mean (SD), y 62.8 (18.8) 59.7 (14.2) 55.9 (14.8) 59.1 (14.3) 65.7 (11.8) 54.4 (18.3) 57.1 (16.0) 59.3 (13.8) 59.1 (15.2)
Men, no. (%) 6 (40.0) 9 (60.0) 10 (71.4) 17 (56.7) 8 (53.3) 10 (66.7) 13 (43.3) 21 (70.0) 94 (57.3)
Black, no. (%) 5 (33.3) 10 (66.7) 7 (50.0) 15 (50.0) 9 (60.0) 10 (66.7) 18 (60.0) 18 (60.0) 92 (56.1)
Hb, mean (SD), g/dL 11.6 (0.6) 11.6 (0.4) 11.7 (0.6) 11.5 (0.7) 11.4 (0.6) 11.5 (0.5) 11.5 (0.6) 11.5 (0.7) 11.5 (0.6)
Kt/V, mean (SD) 1.87 (0.83) 1.61 (0.18) 1.52 (0.22) 1.59 (0.27) 1.69 (0.24) 1.61 (0.29) 1.79 (0.33) 1.69 (0.24) 1.68 (0.36)
Ferritin, mean (SD),
ng/mL
724.1 (212.2) 633.2 (321.2) 635.6 (423.2) 789.2 (510.0) 887.7 (413.4) 1073.9 (643.4) 665.6 (456.6) 564.0 (401.4) 727.1 (458.9)
TSAT, mean (SD),% 36.4 (9.5) 32.5 (4.9) 43.1 (12.0) 50.4 (19.4) 52.8 (17.1) 57.6 (16.3) 31.6 (10.3) 33.3 (12.0) 41.2 (16.5)
CHr, mean (SD), pg 31.7 (1.9) 32.1 (2.6) 32.2 (2.8) 32.4 (2.0) 33.2 (1.7) 32.3 (2.4) 32.3 (1.9) 32.7 (2.3) 32.4 (2.2)
Epoetin alfa dose,
median
143 130 161 124 109 118 132 160 137
(range) (92–377) (70–288) (67–365) (63–277) (59–214) (72–231) (65–327) (80–367) (59–377)
U/kg/wk 9997 12444 12598 9603 9547 7600 7398 7598 8567
U/wk (6371–33650) (4634–21709) (6593–36590) (3602–24597) (4544–30445) (5066–10140) (4797–10666) (965–14820) (965–36590)
Primary cause of CKD,
no. (%)
Diabetes 6 (40.0) 6 (40.0) 6 (42.9) 12 (40.0) 6 (40.0) 3 (20.0) 11 (36.7) 17 (56.7) 67 (40.9)
Hypertension 4 (26.7) 4 (26.7) 2 (14.3) 13 (43.3) 6 (40.0) 9 (60.0) 15 (50.0) 8 (26.7) 61 (37.2)
Other 5 (33.3) 5 (33.3) 6 (42.9) 5 (16.7) 3 (20.0) 3 (20.0) 4 (13.3) 5 (16.7) 36 (22.0)
Abbreviations: SD, standard deviation; Hb, hemoglobin; Kt/V, urea clearance per volume; TSAT, transferrin saturation; CHr, reticulocyte hemoglobin content; CKD,
chronic kidney disease.
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g/dL for most patients during Weeks 2 to 13 (75%) and
Weeks 14 to 25 (79%), regardless of cohort (Table 3); Hb
levels were maintained within 11.0 to 13.0 g/dL in fewer
patients (Additional file 3: Table S3). The lower proportion
of patients may reflect that the dose adjustment guidelines
were designed to keep Hb within ±1.0 g/dL of baseline and
did not target a Hb concentration between 11.0 and 13.0 g/
dL. Overall, however, Hb levels were maintained within 9.5
to 13.0 g/dL and within 11.0 to 13.0 g/dL in a higher pro-
portion of patients in those cohorts in which an ESA-free
interval was used than in those cohorts in which an ESA-Figure 2 Effects of dose conversion ratios (A) vs tiered conversion tabfree interval was not used (Tables 3 and Additional file 3:
Table S3).
Safety
Adverse events were reported in 137 of 164 patients
(84%), of which, 93 patients (68%) had AEs considered
mild to moderate in severity. Table 4 details the most
common (≥5%) AEs. The most common (>1%) AEs con-
sidered by the investigators to be possibly related to
peginesatide were fatigue (1.8%), decreased Hb (1.8%),
asthenia (1.2%), and rash (1.2%). Ten out of 164 patients
reported arteriovenous graft complications; a total of 12les (B) on median peginesatide doses over time.
Figure 3 Effects of not using (A) vs using (B) an erythropoiesis-stimulating agent–free interval on mean hemoglobin levels over time.
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near the time of the complications were between 7.9
and 13 g/dL in all but one patient, who had a Hb of
14.7 g/dL.
Serious adverse events were reported in 47 of 164
patients (29%). Table 5 details the most common (>1
patient) serious adverse events (SAEs). A single SAE (infu-
sion-related reaction, described below) was considered
possibly related to peginesatide. The incidence of AEs ran-
ged from 60% to 93% and SAEs ranged from 13% to 40%
across cohorts without evidence of a relationship between
starting dose and the incidence of either AEs or SAEs.
Five deaths occurred during the course of the study, 1
of which occurred before dosing. The four deaths that
occurred after administration of the first dose of study
drug were due to pneumonia and sepsis, cardiac arrest,
cardiorespiratory arrest, and sepsis and respiratory fail-
ure. None of the deaths were reported as being related
to peginesatide and all were typical of the end stage
renal disease population studied.
Twelve patients were withdrawn from the study because
of AEs. Four of these patients died (as noted above). Five
patients were withdrawn because of serious, nonfatal
events of study drug infusion-related reaction, aspiration

















































First row of each set indicates the total number of patients, second row, the numbevasculitis, aspiration, and vascular pseudoaneurysm. The
event of infusion-related reaction (ie, pruritus, anxiety,
nausea, hypotension, and vomiting) began 2 minutes after
the patient’s first peginesatide dose. After receiving intra-
venous (IV) fluids and antihistamine treatment, the patient
recovered and was discharged on the same day with no
further symptoms; peginesatide treatment was discontin-
ued. The event of leukocytoclastic vasculitis began 35 days
after the patient’s second peginesatide dose (11.2 mg),
4 weeks after beginning clopidogrel treatment, and 11 days
after receiving a flu vaccine. The investigator reported the
event as unlikely to have been related to study drug. Two
patients were withdrawn after receiving renal transplants.
One patient was withdrawn after developing a rash that
was initially pruritic in nature. Of the AEs that led to
patient withdrawal from the study, only the events of rash/
pruritic rash and infusion-related reaction were considered
by the investigators to be possibly related to peginesatide
administration.
A total of 8 patients (4.9%) received red blood cell
transfusions (Cohort D, n = 4; Cohort F, n = 1; Cohort
G, n = 2; Cohort H, n = 1). Five patients received trans-
fusions exclusively for the treatment of anemia. Of the
remaining 3 patients, 1 received two transfusions (1 for





Cohorts With an ESA-
Free Interval (D, E, F)
Cohorts Without an ESA-
Free Interval (A, B, C, G, H)


















r within range and the percentage.
Table 4 Most frequently (occurring in ≥5% of patients)
reported adverse events
Treatment-Emergent Adverse Event, no. (%) Total n = 164











Back pain 10 (6.1)
Hypertension 10 (6.1)
Pain in extremity 10 (6.1)
Hypocalcemia 9 (5.5)
Hypotension 9 (5.5)
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tures), as a postsurgical procedure, and for anemia; and
1 was transfused for postoperative hemorrhage.
One patient in Cohort H had a high Hb concentration
approximately 1 week after receiving the fifth peginesa-
tide injection that remained elevated during the next
11 weeks (range, 12.4 g/dL to 16.7 g/dL). The patient
was phlebotomized (500 mL) 91 days after Dose 5
(201 days after Dose 1) with a decline in Hb level from
16.7 g/dL the day before the phlebotomy to 13.4 g/dL
the day after the procedure and 11.8 g/dL one week
after. This patient was withdrawn from the studyTable 5 Most frequently (occurring in >1 patient)
reported serious adverse events
Serious Adverse Event, no. (%) Total n = 164
Congestive cardiac failure 6 (3.7)
Pneumonia 4 (2.4)
Acute myocardial infarction 3 (1.8)
Convulsion 3 (1.8)
Pulmonary edema 3 (1.8)
Sepsis 3 (1.8)
Catheter sepsis 2 (1.2)
Coronary artery disease 2 (1.2)
Hypotension 2 (1.2)
Pneumonia, aspiration 2 (1.2)
Pulmonary embolism 2 (1.2)
Respiratory failure 2 (1.2)because the need for phlebotomy was a withdrawal
criterion.
Iron levels were satisfactorily maintained throughout
the study, with mean baseline and end-of-study ferritin
values of 727 ng/mL and 742 ng/mL, respectively; mean
baseline and end-of-study transferrin saturation (TSAT)
values of 41% and 49%, respectively; and mean baseline
and end-of-study reticulocyte Hb contents of 32.4 pg
and 34.2 pg, respectively.
Five patients had elevations in alanine aminotransfer-
ase (ALT) ≥3x upper limit of normal (ULN) and/or
aspartate aminotransferase (AST) ≥3x ULN. Three
patients had transient elevations in ALT and/or AST; the
other 2 patients had elevated values at baseline which
were sustained during the study. One patient had transi-
ent elevation in total bilirubin ≥2x ULN. All but 1 of
these patients were receiving concomitant heparin, sta-
tin, and/or aspirin therapy, which have been associated
with elevations in liver function tests. None of the ALT
or AST elevations were associated with a concurrent rise
in total bilirubin ≥2x ULN. No patients developed anti-
bodies specific to peginesatide.
Mean systolic and diastolic blood pressure fluctuated
during the trial for each cohort, with values similar to
those recorded during the screening period while sub-
jects were receiving epoetin alfa.
In general, there were no changes in the interpretation
of ECG results at baseline and 30 minutes after the first
peginesatide dose. No patient had an ECG abnormality
interpreted by the investigator as clinically significant
that was not present at screening.
Discussion
The primary purpose of this study was to determine the
optimal peginesatide dosing strategy to maintain Hb
levels in hemodialysis patients who were previously trea-
ted with epoetin alfa. The strategies that were investi-
gated were 1) single epoetin alfa–to-peginesatide dose
conversion ratios versus tiered conversion tables; and 2)
whether or not an ESA-free interval was used. Overall,
53.6% of patients in this study achieved a Hb level within
±1.0 g/dL of their baseline level by the end of the study
(ie, Weeks 18–25). Of note, per-protocol peginesatide
dose adjustments were allowed after the first dose.
An increase in the median peginesatide dose require-
ment was observed in cohorts that used a single epoetin
alfa–to-peginesatide dose conversion ratio, whereas this
general trend was attenuated in cohorts that used tiered
conversion tables. Initial peginesatide doses that resulted
from a single dose conversion ratio may have been inad-
equate for patients with high epoetin alfa dose require-
ments, indicating that interpatient variability in dose
requirements appears to have been better addressed by
tiered dose conversion tables than it was by a single dose
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alfa–to-peginesatide dose conversion may not be linear.
An alternative explanation is that the initial peginesatide
doses that resulted from tiered dose conversion tables
were higher than those that resulted from a single dose
conversion ratio. However, Cohort C (single dose con-
version ratio) had a similar starting dose as did Cohorts
G and H (tiered dose conversion tables), and the median
dose for Cohort C increased substantially during the
course of the study, whereas dose increases in Cohorts
G and H were less pronounced. These results suggest
that the differences in dose requirements between dos-
ing strategies were not solely due to higher initial doses.
Mean Hb values tended to increase during the first sev-
eral weeks after initiating peginesatide treatment in those
cohorts that did not use an ESA-free interval. Moreover,
Hb levels were maintained within 9.5 to 13.0 g/dL and
within 11.0 to 13.0 g/dL in a higher proportion of patients
in those cohorts in which an ESA-free interval was used.
These data indicate that an ESA-free interval appears to
minimize the initial Hb rise after conversion and may be
beneficial when switching patients from epoetin alfa to
peginesatide. A potential explanation for this may be an
additive effect of the two agents. Epoetin alfa-induced reti-
culocytosis (the pharmacodynamic effect) peaks approxi-
mately 1 to 2 weeks after administration [11], substantially
beyond its thrice-weekly dosing schedule. This effect could
have added to the pharmacodynamic effect of peginesatide
on erythropoiesis and produced an initial increase in Hb
levels from baseline, an effect not seen when the start of
peginesatide was delayed by 1 week.
Similarly to Cohorts A, B, and C, Cohorts G and H did
not have a 1-week ESA-free interval, and an increase in
Hb levels was evident in the first weeks after conversion
to peginesatide; however, Hb levels returned to near-
baseline in Cohorts G and H, whereas they declined to
below baseline levels in Cohorts A, B, and C. This may be
explained by the use of tiered conversion tables in Cohorts
G and H versus the use of a single dose conversion ratio
in Cohorts A, B, and C.
The results of this study did not raise any new concerns
regarding the safety profile of peginesatide; that is, no un-
expected trends emerged with regard to the severity or in-
cidence of AEs, and the safety profile of peginesatide
appeared to be consistent with those of marketed ESAs
[12]. Most of the reported AEs were considered to be un-
related to peginesatide and were generally mild or moder-
ate in intensity. Fatigue, decreased Hb levels, asthenia, and
rash were the most common AEs (>1%) considered by the
investigators to be possibly related to peginesatide. The
observed SAEs were consistent with events that have been
described in dialysis populations with multiple comorbid-
ities [13] and the incidence of SAEs was similar to that
reported in a dose-finding study of peginesatide in CKDnon-dialysis patients [14]. One SAE (infusion-related reac-
tion) was considered possibly peginesatide related. No
neutralizing or non-neutralizing antibodies against pegine-
satide were detected in any patient. Five deaths occurred
during the course of the study, 1 of which occurred before
dosing. Lack of effect was the reason for study discontinu-
ation in less than 5% of patients. This lack of effect could
be explained by transient hyporesponse, which lasts sev-
eral months and can develop in previously stable patients,
or suboptimal dose conversion. This aspect is better stud-
ied in a randomized controlled trial with an active
comparator.
This study had several limitations. For example, it was
open label and did not have an active control arm. Further,
the proportion of Black patients was high (56%) relative to
the proportion in the general US population (37%) [15].
Black patients tend to have higher ESA dose requirements
than do patients of other races [16], complicating extrapola-
tion of the average dose requirements of the general popu-
lation from results of the current study. However, the
proportion of Black patients was similar across cohorts
(other than a somewhat lower proportion in Cohort A), at-
tenuating the possibility that race had an effect on cross-
cohort comparisons. Ferritin and TSAT levels were some-
what high overall at baseline with mean values greater than
the minimum requirements for entry (TSAT >20%, ferritin
>200 ng/mL). However, data from the Centers for Medicare
and Medicaid Services Clinical Performance Measures pro-
ject indicated that mean values for both TSAT and ferritin
were progressively increasing in the US during the period
that the current study was conducted [17]. Although there
were some substantial differences in these parameters be-
tween cohorts, which may affect interpretation of the dos-
ing results, examination of the mean values for TSAT and
Hb levels across cohorts suggest that adequate iron delivery
to the erythron was likely during the study. Additionally,
patients entered the trial with Hb values between 10.0 and
12.5 g/dL and doses were titrated to maintain Hb within
±1.0 g/dL of their baseline value. However, since the time
of the conduct of this study, clinical practice guidelines and
updates to prescribing information have narrowed the Hb
target range to less than 11.0 g/dL in the US and between
10.0 and 12.0 g/dL in the EU to minimize risks associated
with normalizing Hb levels to 13.0 g/dL. Therefore, ex-
trapolating dose requirements from this study are limited
by these differences. Phase 3 randomized, active controlled
studies with peginesatide have since been conducted and
will help to inform the assessment of dosing, efficacy, and
safety in the dialysis patient population [18-20].
Conclusions
The purpose of this study was to evaluate the use of dose
conversion ratios and tiered dose conversion with and
without an ESA-free period as dosing strategies for
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http://www.biomedcentral.com/1471-2369/13/95peginesatide. The results showed that increases in pegine-
satide dose requirements were less apparent in cohorts in
which tiered conversion tables were used and Hb levels
appeared more stable in those cohorts in which an ESA-
free interval was used. These results guided dosing strat-
egies for randomized, controlled phase 3 peginesatide
trials in which patients were randomized to continued
epoetin treatment or conversion to peginesatide treat-
ment. Preliminary results of the phase 3 trials have been
reported in abstract form [18-20].
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